AEROVATE THERAPEUTICS INC (AVTE) Stock Price, Quote, News and Overview
NASDAQ:AVTE - Nasdaq - US0080641071 - Common Stock - Currency: USD
AVTE Quote, Performance and Key Statistics
2.75
+0.07 (+2.61%)
The current stock price of AVTE is 2.75 USD. In the past month the price increased by 10%. In the past year, price decreased by -87.53%.
AVTE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About AVTE
Company Profile
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.
Company Info
AEROVATE THERAPEUTICS INC
930 Winter Street, Suite M-500
Waltham MASSACHUSETTS US
CEO: Timothy P. Noyes
Employees: 51
Company Website: https://www.aerovatetx.com/
Investor Relations: https://ir.aerovatetx.com/
Phone: 16174432400
AEROVATE THERAPEUTICS INC / AVTE FAQ
What is the stock price of AEROVATE THERAPEUTICS INC today?
The current stock price of AVTE is 2.75 USD. The price increased by 2.61% in the last trading session.
What is the ticker symbol for AEROVATE THERAPEUTICS INC stock?
The exchange symbol of AEROVATE THERAPEUTICS INC is AVTE and it is listed on the Nasdaq exchange.
On which exchange is AVTE stock listed?
AVTE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AEROVATE THERAPEUTICS INC stock?
9 analysts have analysed AVTE and the average price target is 2.38 USD. This implies a price decrease of -13.46% is expected in the next year compared to the current price of 2.75. Check the AEROVATE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AEROVATE THERAPEUTICS INC worth?
AEROVATE THERAPEUTICS INC (AVTE) has a market capitalization of 79.72M USD. This makes AVTE a Micro Cap stock.
How many employees does AEROVATE THERAPEUTICS INC have?
AEROVATE THERAPEUTICS INC (AVTE) currently has 51 employees.
What are the support and resistance levels for AEROVATE THERAPEUTICS INC (AVTE) stock?
AEROVATE THERAPEUTICS INC (AVTE) has a support level at 2.61 and a resistance level at 2.76. Check the full technical report for a detailed analysis of AVTE support and resistance levels.
Should I buy AEROVATE THERAPEUTICS INC (AVTE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVTE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVTE, evaluating the profitability, health, valuation and growth aspects
- AEROVATE THERAPEUTICS INC (AVTE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AEROVATE THERAPEUTICS INC (AVTE) Sales and EPS estimates to see what analysts future expectations are.
- AEROVATE THERAPEUTICS INC (AVTE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AEROVATE THERAPEUTICS INC (AVTE) Insider and Institutional Ownership to learn about the owners and their transactions.
- AEROVATE THERAPEUTICS INC (AVTE) Stock Chart to make your own analysis
- AEROVATE THERAPEUTICS INC (AVTE) Latest news and press-releases to stay up to date.
Does AEROVATE THERAPEUTICS INC (AVTE) stock pay dividends?
AVTE does not pay a dividend.
When does AEROVATE THERAPEUTICS INC (AVTE) report earnings?
AEROVATE THERAPEUTICS INC (AVTE) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of AEROVATE THERAPEUTICS INC (AVTE)?
AEROVATE THERAPEUTICS INC (AVTE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.44).
What is the Short Interest ratio of AEROVATE THERAPEUTICS INC (AVTE) stock?
The outstanding short interest for AEROVATE THERAPEUTICS INC (AVTE) is 14.99% of its float. Check the ownership tab for more information on the AVTE short interest.
AVTE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AVTE. When comparing the yearly performance of all stocks, AVTE is a bad performer in the overall market: 87.96% of all stocks are doing better.
AVTE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVTE. No worries on liquidiy or solvency for AVTE as it has an excellent financial health rating, but there are worries on the profitability.
AVTE Financial Highlights
Over the last trailing twelve months AVTE reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 15.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.68% | ||
| ROE | -91.1% | ||
| Debt/Equity | 0 |
AVTE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to AVTE. The Buy consensus is the average rating of analysts ratings from 9 analysts.